Skip to main content

Legault Pierre's Form 4 filing

Syndax Pharmaceuticals Inc (SNDX) · filed Dec 22, 2021

Accession no.
0001562180-21-007866
Filed
Dec 22, 2021
Trade date
Dec 20-22, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $948.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Legault PierreCIK 0001391045Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 20, 2021Common StockMOption exerciseAcquired+20,000$7.08+$141,60036,000Direct
Dec 20, 2021Common StockSSaleDisposed−20,000$21.01F2−$420,20016,000Direct
Dec 22, 2021Common StockMOption exerciseAcquired+24,000$7.88+$189,12040,000Direct
Dec 22, 2021Common StockSSaleDisposed−24,000$22.01F3−$528,24016,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 20, 2021Common StockMOption exerciseDisposed−20,000$0.00$00Direct
Dec 22, 2021Common StockMOption exerciseDisposed−24,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The sale prices ranged from $21.00 to $21.0238.

Referenced by the price of 1 transaction in Table I.

F3

The sale prices ranged from $22.00 to $22.02.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)